GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » Asset Turnover

Immunome (Immunome) Asset Turnover : 0.00 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Immunome Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Immunome's Revenue for the three months ended in Mar. 2024 was $1.03 Mil. Immunome's Total Assets for the quarter that ended in Mar. 2024 was $234.15 Mil. Therefore, Immunome's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Immunome's annualized ROE % for the quarter that ended in Mar. 2024 was -255.50%. It is also linked to ROA % through Du Pont Formula. Immunome's annualized ROA % for the quarter that ended in Mar. 2024 was -221.21%.


Immunome Asset Turnover Historical Data

The historical data trend for Immunome's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunome Asset Turnover Chart

Immunome Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial - - - - 0.16

Immunome Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.10 0.05 0.03 -

Competitive Comparison of Immunome's Asset Turnover

For the Biotechnology subindustry, Immunome's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immunome's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Immunome's Asset Turnover falls into.



Immunome Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Immunome's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=14.018/( (24.046+148.54)/ 2 )
=14.018/86.293
=0.16

Immunome's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=1.029/( (148.54+319.754)/ 2 )
=1.029/234.147
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Immunome  (NAS:IMNM) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Immunome's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-517.968/202.727
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-517.968 / 4.116)*(4.116 / 234.147)*(234.147/ 202.727)
=Net Margin %*Asset Turnover*Equity Multiplier
=-12584.26 %*0.0176*1.155
=ROA %*Equity Multiplier
=-221.21 %*1.155
=-255.50 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Immunome's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=-517.968/234.147
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-517.968 / 4.116)*(4.116 / 234.147)
=Net Margin %*Asset Turnover
=-12584.26 %*0.0176
=-221.21 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Immunome Asset Turnover Related Terms

Thank you for viewing the detailed overview of Immunome's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunome (Immunome) Business Description

Traded in Other Exchanges
N/A
Address
665 Stockton Drive, Suite 300, Exton, PA, USA, 19341
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. It primarily operates in the U.S. Its current programs comprise Oncology (IMM-ONC-01), SARS-CoV-2 (IMM-BCP-01), and IMM20059 Anti-EPN1.
Executives
Jean Jacques Bienaime director 925 PAGE MILL ROAD, PALO ALTO CA 94304
Robert Lechleider officer: Chief Medical Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341
Max Rosett officer: SVP Operations C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Clay B Siegall director, officer: President and CEO 21823 30TH DR SE, BOTHELL WA 98021
Jack Higgins officer: Chief Scientific Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Isaac Barchas director, other: See remarks 1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201
Bruce Turner officer: Chief Strategy Officer C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
James P Boylan director C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Matthew K Robinson officer: Chief Technology Officer C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341
Michael Rapp director, 10 percent owner 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Franklyn G Prendergast director
Michael Lefenfeld director IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
Purnanand D Sarma director, officer: President and CEO IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
John L Lamattina director 81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Philip Wagenheim director 712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019